FDA-Approved Excipient N,N-Dimethylacetamide Attenuates Inflammatory Bowel Disease in In-Vitro and In-Vivo Models

Jagadish Koya  
St. John's University

Tong Shen  
Mount Sinai Medical Center

Geming Lu  
Mount Sinai Medical Center

Alex Gauthier  
St. John's University

Lin Mantell  
St. John's University

Charles Ashby  
St. John's University

Sandra Reznik (✉ rezniks@stjohns.edu)  
St. John's University

Research Article

Keywords: N,N-dimethylacetamide, inflammatory bowel disease, nuclear factor kappa B, inflammation, excipient

Posted Date: October 13th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-948100/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Inflammatory bowel disease (IBD) affects almost 7 million people worldwide and is increasing in incidence. While the precise pathogenesis of IBD remains unknown, the production of inflammatory cytokines and chemokines play a central role. We have previously found that N,N-dimethylacetamide (DMA), a widely used non-toxic drug excipient, suppresses cytokine and chemokine secretion in vitro and prevents inflammation-induced preterm birth in vivo. Using sandwich enzyme-linked immunosorbent assays (ELISAs), we tested whether DMA attenuates cytokine and chemokine secretion from LPS- or TNFα-stimulated human intestinal epithelial cells and human monocytes and HMGB1 release from RAW 264.7 cells. To test our hypothesis that the mechanism of DMA's effects in in-vitro and in-vivo models of IBD is inhibition of the NF-kB pathway, we used western blotting to track levels of the nuclear factor kappa B (NF-kB) inhibitory molecule I kappa B alpha (IkBa) in THP-1 human monocytes in the absence or presence of DMA. Finally, we induced colitis in C57Bl/6 mice with dextran sodium sulfate (DSS) and then tested whether daily i.p injections of DMA at 2.1 g/kg/day attenuates clinical and histopathologic signs of colitis. DMA attenuated cytokine and chemokine release from human intestinal epithelial cells and human monocytes and HMGB1 release from RAW 264.7 cells. Importantly, DMA prevented degradation of IkBa in THP-1 cells, thereby suggesting one mechanism for DMA's effects. Finally, we show here, for the first time, that DMA attenuates clinical and histologic features of DSS-induced colitis. Based on these data, DMA should be further explored in preclinical and clinical trials for its potential as novel drug therapy for IBD.

Introduction

Inflammatory bowel disease (IBD) is a group of chronic inflammatory conditions of the gastrointestinal tract, which includes Crohn's disease and ulcerative colitis [1]. Patients with IBD suffer from concomitant chronic diseases and infectious conditions, including cardiovascular disease, respiratory disease, digestive disease, malignancy and osteoporosis [2, 3]. An estimated 6.8 million people worldwide currently suffer from IBD [4] and its prevalence more than doubled in the United States from 2009-2016 [5].

While the precise etiology of IBD remains unknown, the production of pro-inflammatory cytokines, such as TNFα, Interleukin (IL)-1b and IL-6 [6, 7] and chemokines such as IL-8, which recruits neutrophils to sites of tissue injury [8–11] are central to the pathogenesis of this disorder. These cytokines are secreted from both intestinal epithelial cells and intestinal macrophages [9, 12–14]). One driver of these pro-inflammatory responses is high mobility group box 1 (HMGB1), a ubiquitous nuclear protein that activates innate immune responses when released from cells [15]. HMGB1 has been recently recognized as a therapeutic target in various inflammatory diseases [16–19], including IBD [20].

We have previously reported that N,N-dimethylacetamide (DMA), a widely used drug excipient, formerly believed to be inert, attenuates inflammation-induced preterm birth in mice by preventing nuclear factor kappa B (NF-kB) activation [21]. We have also shown that DMA suppresses cytokine secretion in
lipopolysaccharide (LPS)-challenged RAW 264.7 cells, tumor necrosis factor alpha (TNFa)-induced human placental JEG-3 cells and LPS-stimulated human placental explants [22]) specifically by acting on the NF-kB pathway. Ghayor et al. have shown that DMA prevents osteoporosis in rats via the inhibition of osteoclast mediated bone resorption [23] and enhances bone regeneration impaired by excess inflammation [24]. In other re-purposing studies, DMA has been shown to prevent high-fat diet induced weight gain [25] and has been investigated as a potential reversible contraceptive [26]. Ghayor et al.’s observation that DMA acts by inhibiting NF-kB is consistent with our findings [21–23]. Given DMA’s mechanism of action as an NF-kB inhibitor and given the well-known role of NF-kB in inducing intestinal mucosal inflammation and IBD [27, 28], we hypothesized that DMA would attenuate DSS-induced colitis by inhibiting activation of NF-kB.

Methods

Cell culture and reagents. The human monocyte THP-1 (ATCC TIB-202) cell line; the human colon epithelial cell lines HT-29, HCT-116 and SW 620; and the mouse macrophage RAW 264.7 cell line were purchased from the American Type Culture Collection (Manassas, VA, USA). HT-29, HCT-116, SW 620 and RAW 264.7 cells were cultured in complete growth media (CGM) using Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5 g/L glucose, L-glutamine and sodium pyruvate (Cellgro, Corning, NY) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Atlanta Biologics, Lawrenceville, GA) and 1% penicillin-streptomycin (Cellgro, Corning, NY). THP-1 cells were grown in Roswell Park Memorial Institute (RPMI) medium with L-glutamine (Cellgro, Corning, NY) supplemented with 10% heat-inactivated FBS and 1% penicillin-streptomycin. T84 cells were grown in complete growth medium, which is a 1:1 Dulbecco’s Modified Eagle’s Medium (DMEM) and Ham’s F12 medium with 2.5 mM L-glutamine and supplemented with 5% heat-inactivated fetal bovine serum (FBS). All cells were maintained in an incubator set at 37°C and 5% CO₂ and allowed to grow to 80-90% confluence before being sub-cultured or used in experiments. Purity of DMA was confirmed by gas chromatography-mass spectroscopy. All other reagents were purchased from Sigma-Aldrich (St. Louis, MO) or VWR (Bridgeport, NJ).

MTT assay for cell viability. Cell viability assays were performed as previously described (Pekson et al. 2016). A solution of 3-(4,5-dimethyl thiazolyl-2)-2,5-diphenyl tetrazolium bromide (MTT) was prepared in phosphate buffered saline (PBS) at a concentration of 5mg/ml. HCT-116, SW620, and HT-29 cells were seeded at 18,000 cells/well whereas THP-1 cells were seeded at 30,000 cells/well in 96-well plates and incubated at 37°C and 5% CO₂ overnight. The next day, cells were washed with phosphate buffered saline (PBS), pre-treated with different concentrations of DMA (0.01, 0.1, 1, 10, 20, 30, 40, 50 and 100 mM) in CGM for 2 h and then treated with LPS (Escherichia coli 026:B6) (Sigma, St. Louis, MO) at 1 µg/ml and human-tumor necrosis factor alpha (TNF-α) (R and D systems, Minneapolis, MN) at 40 ng mL⁻¹ for 24 h. At the end of 24 h of treatment, 20 µl of MTT solution (5 mg/ml) (Alfa Aesar, Ward Hill, MA) was added to each well at a final concentration of 0.5 mg/ml. After incubation for 2 h at 37°C and 5% CO₂, media was aspirated and dimethyl sulfoxide (DMSO) (100 µl/well) (BDH, Randor, PA) was added to dissolve formed purple formazan crystals. The plates were shaken on an orbital microplate shaker for 10 min to ensure
complete solubilization of the crystals and the absorbance of the resulting purple solution was measured at 570 nm using an Opsys MR microplate reader (Dynex Technologies, Chantilly, VA).

**Enzyme-linked immunosorbent assay (ELISA).** Sandwich ELISA was used to determine the levels of various cytokines and chemokines such as TNF-α, Interleukin (IL)-6, IL-1β, IL-8, monocyte chemoattractant protein (MCP), granulocyte-macrophage colony-stimulating factor (GM-CSF)-1 and IL-10 and high mobility group box 1 protein (HMGB1) in cell culture supernatants. Ready-SET-Go! sandwich ELISA kits (eBioscience, San Diego, CA) for various human cytokines and chemokines were used as per manufacturers’ protocols. First, the optimal sample dilution for each target cytokine was determined to ensure that the sample absorbance readings fall within the range of their respective standard curves. Standard curves were produced by serially diluting lyophilized or recombinant standards, provided with the kits, according to the manufacturers’ instructions.

As per manufacturers’ protocols, clear flat-bottom Maxisorp 96-well plates (Thermo Fisher Scientific, Waltham, MA) were coated and incubated overnight at 4°C with capture antibody diluted in coating buffer for each analyte. The following day, each well was washed with washing buffer (1X PBS with 0.05% Tween 20) three times and then blocked for non-specific binding sites with assay buffer for one h. Samples were added to the wells in duplicate undiluted or diluted with assay buffer and incubated at for 2 h at room temperature. After the incubation period, each well was washed three times and the detection antibody diluted in assay buffer for the respective analytes was added and samples were incubated for one more h. Following the detection antibody incubation each well was washed thrice and avidin-HRP labeled secondary antibody diluted in assay buffer was added and incubated for another 30 min. Before proceeding to the last step, wells were washed five times and tetramethylbenzidine (TMB) substrate was added and the samples were incubated for 15 min, which resulted in a blue-colored solution. After 15 min., the reaction was concluded by adding a stop solution (1M H₃PO₄), turning the blue solution to yellow and the sample absorbance was measured at 450 nm using an Opsys MR microplate reader. The concentration of each analyte was interpolated using a second order polynomial equation created from the standard curve, using GraphPad Prism 6 software, and then the value was multiplied by the dilution factor used in the assay to calculate the concentration of the analyte in the original undiluted sample.

**Protein immunoblotting.** To study the mechanism of DMA’s effect on cytokine secretion, its effect on nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IkBa) expression in LPS stimulated THP-1 cells was examined. To perform the experiment, THP-1 cells were seeded at a density of 3 x 10⁶ per T25 cm² tissue culture flask and incubated overnight at 37°C and 5% CO₂ using respective CGM. The next day, cells were washed with sterile PBS and pre-treated with different concentrations of DMA (0.1, 1 or 10 mM) or plain CGM for the untreated group, for 2 h. Then, LPS was added to all cells, except for the untreated group, at a final concentration of 1 µg/ml and cells were incubated for another 30 min. Whole cell lysates were prepared at the end of the respective treatment periods as described below.
Preparation of whole cell lysates. Whole cell lysates were prepared using a modified protocol as described by Abcam. Cells were scraped off using a cell scraper (Greiner Bio-one, Monroe, NC) and collected in a pre-chilled 5 ml snap cap centrifuge tube and then centrifuged at 14,000 x g for 2 min. The old medium was aspirated from the 5 ml tubes and cells were washed twice with ice-cold PBS. The washed pellets were again collected into 1.5 ml pre-chilled centrifuge tubes and were then centrifuged at 1000 x g for 5 min. The supernatants were removed without disturbing the cell pellets, which were washed with ice-cold PBS once again and centrifuged at the same settings as mentioned above. Again, the supernatants were removed without disturbing the cell pellets and the pellets were resuspended in 65 µl of radio immunoprecipitation assay (RIPA) lysis and extraction buffer (G-Biosciences, St. Louis, MO). The RIPA lysis buffer was freshly supplemented with EDTA-free protease inhibitor cocktail set III (Calbiochem, San Diego, CA) (1:200 dilution) and with phenylmethylsulfonylfluoride (PMSF) (Calbiochem, San Diego, CA) at a concentration of 100 mM in ethanol (1:100 dilution). The cell pellets were thoroughly mixed with the prepared lysis buffer and were kept on ice with vortexing for 5 sec every 10 min., for a total of 30 min. The lysed cells were centrifuged at 14,000 x g for 20 min. at 4°C (Eppendorf 5424R, Hauppauge, NY). The whole cell lysates were collected in labelled 0.65 ml microcentrifuge tubes and stored at -80°C until further analysis.

Automated capillary western blot analysis (WES Simple Western). WES, an automated capillary-based electrophoresis system (ProteinSimple, San Jose, CA) was used for performing the protein expression analysis. The total protein concentration of each experimental sample was calculated using Pierce bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific, Waltham, MA). The volumes of the lysates used for WES analysis were determined based on total protein concentrations, using a bovine serum albumin (BSA) (Thermo Fisher Scientific, Waltham, MA) standard curve. The final concentration of protein loaded into the WES plate is optimized to be 1µg/ml. All the reagents required for WES were prepared as per the manufacturer's instructions. The provided 10X sample buffer was diluted using ultrapure water to 0.1X, which was used to dilute lysates. First, all standard pack reagents (DTT, 5X Fluorescent master mix and biotinylated ladder) were prepared. Then the lysates were mixed with prepared 5X fluorescent master mix in a 4:1 ratio to have the final concentrations of the lysates at 1 µg/µl. Finally, the lysates were heated at 95°C for 5 min.

The prepared lysates, blocking reagent, primary antibodies, HRP-conjugated secondary antibodies, chemiluminescent substrate mix (Luminol:Peroxide mixture in 1:1 ratio) and wash buffer were dispensed into designated wells in an assay plate provided by the manufacturer and as per the manufacturer's instructions. The assay plate, along with the respective capillary cartridge, was placed into the WES instrument (ProteinSimple, San Jose, CA), which carries out all further assay steps automatically using default settings. Anti-Î·Bα antibody(Cell Signaling technologies, Danvers, MA), diluted 1/50, was used as the primary antibody and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (Cell Signaling Technologies, Danvers, MA), diluted 1/10,000, was used for the gel loading control. All primary antibodies were diluted in an antibody diluent provided by the manufacturer and the optimal dilution for each primary antibody was determined using Simple Western antibody database as a reference. In approximately 3 h, molecular weight and quantitative signals for target proteins were automatically
reported by the Compass software (ProteinSimple, San Jose, CA). Protein expression was analyzed using ImageJ software (NIH, Bethesda, MD) and normalized to that of GAPDH.

**Animals.** Nine-week-old male C57Bl/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME). All experimental protocols were approved by the Mount Sinai Medical Center Institutional Animal Care and Use Committee (IACUC). All methods were carried out in accordance with relevant guidelines and regulations. All methods are reported in accordance with ARRIVE guidelines (https://arriveguidelines.org). Mice were euthanized by carbon dioxide asphyxiatiation.

In vivo studies on the effect of DMA on dextran sodium sulphate (DSS)-induced colitis. Animal studies were approved. Colitis was induced with DSS. A total of ten male C57Bl/6 mice weighing between 20 and 28 g were given drinking water containing 2.5% DSS. Mice were then randomly assigned to two groups. Group I mice (n=5) were negative controls and were injected intraperitoneally (ip) with 0.2 mL of PBS once a day for nine days. Group II mice (n=5) were injected ip with 0.2 mL of 33% DMA (2.1 g/kg) once a day for four days. One sham mouse was allowed to drink plain drinking water and injected with 0.2 mL PBS once a day for nine days. Mice were euthanized on the ninth day of the experiment and necropsied. The intestines were removed in their entirety for histologic examination.

**Histological evaluation and grading.** Several sections of the distal portion of the colon from each mouse were fixed in formalin, paraffin embedded, sectioned at 4 µM and stained with hematoxylin and eosin. Sections were examined by a practicing anatomic pathologist, who was blinded to the experimental conditions (S.E.R.), and scored, following the method described by Laroui et al. [41]. Each section was scored for severity of inflammation (0 = rare inflammatory cells in the lamina propria, 1 = increased inflammatory cells in the lamina propria, 2 = confluence of inflammatory cells extending into the submucosa, 3 = transmural inflammation); crypt injury (0 = intact crypts, 1 = loss of the basal one third of crypts, 2 = loss of the basal two thirds of crypts, 3 = loss of entire length of crypts, 4 = focal erosion of epithelial surface, 5 = confluent areas of erosion of the epithelium); and ulceration (0 = absence of ulceration, 1 = 1 or 2 foci of ulceration, 2 = 3 or 4 foci of ulceration, 3 = confluent ulceration). Scores were added to yield maximum histologic grade of 11. Sections were examined with a Nikon Eclipse 80i light microscope and images were captured with a Nikon Digital Sight camera (Nikon, Melville, NY).

**Statistical analysis.** All the data are represented as the mean +/- SEM of at least four independent experiments. The data were analyzed using GraphPad Prism 6 software (San Diego, CA, USA). The statistical significance among and between groups was tested using a one-way analysis of variance (ANOVA), followed by Tukey’s multiple comparison post hoc test for the cell viability, cytokine secretion, and immunoblotting protein analyses. The Kruskal Wallis test was used to analyze differences in histologic scores. The a priori significance value was P<.05.

**Results**

**Cell viability.** The effect of various concentrations of DMA on the viability of HT-29, HCT-116, SW620 and THP-1 cells was determined in order to identify a non-toxic range of concentrations that could be used in
DMA was found to produce no significant change in cell viability at concentrations up to at least 10 mM in all four cell lines in unstimulated cells (Supplementary Figure 1), in all four cell lines with stimulation by 1 µg mL\(^{-1}\) LPS (Supplementary Figure 2) and in the three colonic epithelial cell lines with stimulation by TNFα (Supplementary Figure 3). Therefore, in vitro assays were carried out with no more than 10 mM DMA.

**DMA attenuates IL-8 secretion from HT-29, HCT-116, SW620 cells.** DMA significantly attenuated IL-8 secretion in HT-29 cells (Figure 1A) and HCT-116 cells (Figure 1B) stimulated with 1 µg/mL of LPS at a concentration of 10 mM and significantly decreased IL-8 secretion in LPS stimulated SW620 cells at both 1 and 10 mM (Figure 1C). Concentrations as low as 0.1 mM of DMA attenuated IL-8 secretion in HT-29 cells (Figure 2A) and concentrations of 1 mM and above reduced IL-8 secretion in SW620 cells (Figure 2B) stimulated with 40 ng\(^{-1}\) TNFα.

**DMA attenuates pro-inflammatory cytokine secretion from THP-1 cells.** While colonic epithelial cells are likely a relatively minor source of inflammatory cytokines in vivo, monocytes and macrophages contribute significantly to the cytokine response in IBD. Therefore, we tested the ability of DMA to suppress cytokine secretion in THP-1 cells, a human monocyte line. In THP-1 cells stimulated with 1 µg mL\(^{-1}\) LPS, DMA significantly reduced IL-1β secretion at 10 mM (Figure 3A), IL-6 secretion at 1 and 10 mM (Figure 3B), IL-8 secretion at 10 mM (Figure 3C), MCP-1 secretion at 10 mM (Figure 3D) and IL-10 secretion at 10 mM (Figure 3E). BAY 11-7082, an NF-kB inhibitor (is used at 5 µM as a positive control.

**DMA prevents IkBα degradation in THP-1 cells.** To test whether DMA affects levels of IkBα in THP-1 cells, the time course of IkBα degradation in THP-1 cells stimulated with 1 µg mL\(^{-1}\) LPS was examined, using immunoblotting. Lowest levels of IkBα were found in cell lysates at 30 min (Supplemental Figure 4). Therefore, DMA’s effect on IkBα degradation was evaluated in THP-1 cells stimulated with LPS for 30 min. DMA protected IkBα from LPS-induced degradation at 0.1, 1 and 10 mM (Figure 4).

**DMA attenuates HMGB1 secretion from RAW 264.7 cells at micromolar concentrations.** HMGB1 secretion reflects oxidative stress, a key component of the pathogenesis of IBD. In addition, HMGB-1 activates the NF-kB pathway. Interestingly, DMA prevented HMGB1 secretion from LPS stimulated RAW 264.7 cells, a well characterized mouse macrophage cell line known to secrete HMGB1, at all concentrations tested (Figure 5).

**DMA attenuates DSS-induced colitis.** Control DSS challenged mice (n=5) all developed bloody diarrhea by the eighth day of the experiment, whereas all the DMA rescued DSS challenged mic (n=5) developed bloody diarrhea on the ninth day of the study. In addition, histologic analysis of intestinal sections from the DSS control mice showed inflammation, crypt injury and ulceration, but these effects were attenuated by DMA with significant reduction in crypt injury (\(P<.05\)) and total histologic scores (\(P<.05\), Figure 6). Mean histologic scores for inflammation in DSS challenged mice with and without DMA rescue were 2.4 ± 0.9 and 3.0, respectively. Mean scores for crypt injury for the two groups were 3.8 ± 0.8 and 5.0, respectively (\(P<.05\)). Mean scores for ulceration for these two groups were 2.2 ± 0.8 and 3, respectively.
Finally, mean total histologic scores were 8.4 ± 2.1 and 11.0, respectively (P<.05). Raw histologic scoring data are provided in Supplementary Table 1.

Discussion

While the precise etiology of IBD remains elusive, it is clear that NF-κB driven pro-inflammatory responses play a central role. Current pharmacotherapeutic approaches to IBD, such as sulfasalazine and biologics, work by preventing activation of the NF-κB pathway either directly or indirectly [29, 30]. However, sulfasalazine, while it attenuates IBD symptoms and is readily accessible, does not show efficacy in some patients and, like all sulfonamides, is associated with hepatotoxicity [31]. On the other hand, biologics, such as monoclonal antibodies, may have greater efficacy, but remain extremely expensive [32]. DMA is an inexpensive, non-toxic widely used drug excipient, which has been previously shown by us and others to inhibit NF-κB [21, 23] and which has been proven to be non-toxic in pediatric cancer patients found to have plasma concentrations in the mM range [33]. Therefore, we hypothesized that DMA would attenuate DSS-induced colitis.

After establishing the highest non-toxic concentration of DMA in cell viability assays, we proceeded to investigate the effect of DMA on inflammatory mediators (cytokines and chemokines) in human IECs and in human monocytes. Initially, we screened for the presence of cytokines and chemokines including TNF-α, IL-6, IL-1β, IL-8, IL-10, MCP-1, and GM-CSF in the three IEC cell lines and the monocytes. The stimulated IECs, which are not immune in origin, only upregulated the production of IL-8. Chemokine IL-8 recruits neutrophils to sites of tissue injury [34] and triggers the formation of crypt abscesses, a predominant feature in UC. Moreover, levels of neutrophils in colonic biopsies from UC patients are proportional to levels of disease severity [10, 11]. DMA, at 10 mM, attenuated IL-8 secretion from the IECs stimulated with either LPS or TNFa, which is consistent with our previous finding that DMA decreases neutrophil counts in placentas harvested from LPS-stimulated pregnant C57Bl/6 mice [21].

In addition to investigating DMA’s effect on IL-8 secretion from IECs, we tested DMA’s effect on the secretion of various cytokines from LPS-stimulated THP-1 monocytes. Monocytes reside under the lamina propria in the intestine, express toll-like receptor (TLR)-4 on their surface and play an active part in producing chronic gut inflammation [35, 36]. Cytokines IL-6, IL-1β and IL-10 and chemokines IL-8 and MCP-1 were significantly reduced with treatment of DMA at 10 mM in THP-1 cells. Consistent with these results, levels of IL-6 and IL-1β are positively correlated with disease severity in both Crohn’s disease and UC [37, 38]. While IL-10 is classically considered an anti-inflammatory cytokine, it has also been reported to show immune stimulatory effects by upregulating major histocompatibility class II expression in B-lymphocytes, inducing cytotoxic T-cell differentiation [39]. Moreover, IL-10 deficient mice develop colitis [40]. It is likely that IL-10 is acting as a pro-inflammatory cytokine in our cultured THP-1 cells.

Importantly, we show here that DMA inhibits degradation of the NF-κB inhibitory molecule IkBa in THP-1 cells. This finding is consistent with our previously reported result that DMA prevents IkBa degradation in RAW 264.7 cells [22] and suggests one mechanism whereby DMA prevents NF-κB driven up-regulation of
cytokines and chemokines. In addition, we demonstrate that DMA decreases HMGB1 secretion from RAW 264.7 cells. HMGB1, when secreted, acts as a pro-inflammatory mediator. DMA's ability to prevent HMGB1 release from cells, therefore, reinforces its effect on NF-kB signaling. Interestingly, DMA prevents HMGB1 secretion at 0.1 mM, whereas much higher concentrations of DMA are required to produce its effects on cytokine levels. This suggests that while decreased HMGB1 release may contribute to DMA's anti-inflammatory effects, reduced HMGB1 secretion alone does not fully account for DMA's mechanism of action. Ghayor et al. have also shown that DMA is a bromodomain ligand [23], a result that we have confirmed in our laboratory. Taken together, the data suggest that DMA, a small, highly soluble molecule, may act via multiple mechanisms.

Finally, we show here, for the first time, that DMA attenuates DSS-induced colitis in a murine model. In particular, DMA prevents the formation of crypt abscesses, a hallmark feature of UC in human patients. We also show that DMA prevents NF-κB transcriptional activity by inhibiting IkBα degradation. It is likely that DMA acts by multiple mechanisms. Taken together, the data indicate that DMA should be further investigated as potential drug therapy for IBD.

Declarations

Ethics Approval and Consent to Participate
N/A

Consent for Publication
N/A

Availability of Data and Materials

The data that support the findings in this study are available from the corresponding author upon reasonable request.

Competing Interests

SER and CRA Jr. have a patent pending (US 13/536,946) on the use of N, N-dimethylacetamide for inflammatory disorders.

Funding

This work was supported by funds from the St. John's University department of pharmaceutical sciences and a contract with the Nassau Health Care Corporation.

Authors’ Contributions
JBK performed most of the experiments and contributed to the writing of the manuscript. TS and GL performed the in vivo study. AG and LM performed the HMGB1 experiment. CRA helped to conceive the project. SER conceived the project, significantly contributed to the writing of the manuscript and provided funding.

Acknowledgments

We are grateful to the animal care facility staff at the Icahn School of Medicine at Mount Sinai, New York, NY for the housing and care of the mice.

References

1. Peyrin-Biroulet, L., Christopher, R., Behan, D. & Lassen, C. Modulation of sphingosine-1-phosphate in inflammatory bowel disease. *Autoimmun Rev, 16*, 495–503 (2017).
2. Xu, F., Dahlhamer, J. M., Zammitti, E. P., Wheaton, A. G. & Croft, J. B. Health-risk behaviors and chronic conditions among adults with inflammatory bowel disease—United States, 2015 and 2016. *Morbidity and Mortality Weekly Report, 67*, 190 (2018).
3. Olén, O. et al. Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964–2014., *69*, 453–461 (2020).
4. Alatab, S. et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol, 5*, 17–30 (2020).
5. Ye, Y., Manne, S., Treem, W. R. & Bennett, D. (2020) Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007–2016. Inflam Bowel Dis. 2020;26:619-625.
6. Shih, D. Q. & Targan, S. R. Immunopathogenesis of inflammatory bowel disease. *World J Gastroenterol*, 14, 390 (2008).
7. Torres, M. & Ríos, A. Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy. *World J Gastroenterol*, 14, 1972–1980 (2008).
8. Cui, L., Feng, L., Zhang, Z. H. & Jia, X. B. The anti-inflammation effect of baicalin on experimental colitis through inhibiting TLR4/NF-κB pathway activation. *Int Immunopharmacol, 23*, 294–303 (2014).
9. Waugh, D. J. & Wilson, C. The interleukin-8 pathway in cancer. *Clin Cancer Res, 14*, 6735–6741 (2008).
10. Mitsuyama, K. et al. (1994) IL-8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease. Clin Exper Immunol. 1994;96:432-36.
11. Daig, R. et al. (1996) Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut. 1996;38:216-22.
12. Hendrickson, B. A., Gokhale, R. & Cho, J. H. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev, 5, 79–94 (2002).
13. Atreya, R. et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nature Med, 6, 583–588 (2000).
14. Roda, G. et al. Crohn's disease. Nature Rev Dis Primers, 6, 1–19 (2020).
15. Yang, H., Wang, H. & Andersson, U. Targeting inflammation driven by HMGB1. Front Immunol, https://doi.org/10.3389/fimmu.2020.00484 (2020).
16. Yang, H. & Tracey, K. J. Targeting HMGB1 in inflammation. Biochim Biophys Acta, 1799, 149–156 (2010).
17. Andersson, U. & Tracey, K. J. HMGB1 is a therapeutic target for sterile inflammation and infection. Ann Rev Immunol, 29, 139–162 (2011).
18. Kang, R. et al. HMGB1 in health and disease. Mol Aspects Med, 40, 1–116 (2014).
19. Andersson, U., Yang, H. & Harris, H. Extracellular HMGB1 as a therapeutic target in inflammatory diseases. Expert Opin Ther Targets, 22, 263–277 (2018).
20. Hu, Z. et al. Brit J Role of high-mobility group box protein in inflammatory bowel disease. Brit J Pharm, 124, 131–133 (2015).
21. Sundaram, S. et al. N,N-Dimethylacetamide regulates the proinflammatory response associated with endotoxin and prevents preterm birth. Am J Pathol, 183, 422–430 (2013).
22. Pekson, R. et al. (2016) N,N-Dimethylacetamide significantly attenuates LPS- and TNFα-Induced proinflammatory responses via inhibition of the nuclear factor kappa B pathway. Mol Med. 2016; 22:747-758.
23. Ghayor, C. et al. N,N-dimethylacetamide a drug excipient that acts as bromodomain ligand for osteoporosis treatment. Sci Rep, 7, 42108 (2017).
24. Siegenthaler, B., Ghayor, C., Ruangsawasdi, N. & Weber, F. The release of the bromodomain ligand N,N-dimethylacetamide adds bioactivity to a resorbable guided bone regeneration membrane in rabbit calvarial defect model. Materials (Basel), 13, 501 (2020).
25. Bhattacharya, I., Ghayor, C., Pérez, D. A. & Weber, F. E. N,N-Dimethylacetamide prevents high-fat diet-induced increase in body weight. Front Pharmacol, 10, 1274 (2019).
26. Khera, N. et al. Reversible contraceptive potential of FDA approved excipient N,N-dimethylacetamide in male rats. Front Physiol. 2020;Nov 10;11601084.
27. Atreya, I., Atreya, R. & Neurath, M. F. NF-kappaB in inflammatory bowel disease. J Intern Med, 263, 591–596 (2008).
28. Ardite, E. et al. Effects of steroid treatment on activation of nuclear factor kB in patients with inflammatory bowel disease. Brit J Pharmacol, 124, 431–433 (1998).
29. Khanna, R. & Marshall, J. K. Sulfasalazine and 5-aminosalicylates for ulcerative colitis. In Crohn's Disease and Ulcerative Colitis, Baumgart DC (ed). Springer International Publishing. 2017;389-98.
30. Hindryckx, P. & D’Haens Geert Biological therapy of Crohn’s disease: Natalizumab, Velolizumab, and anti-MadCAM. In Crohn’s Disease and Ulcerative Colitis, Baumgart DC (ed)Springer International Publishing. 2017;375-380.

31. European Association for the Study of the Liver. Clinical practice guidelines: Drug-induced liver injury. J Hepatol, 70, 1222–1261 (2019).

32. Chen, B. K., Yang, Y. T. & Bennett, C. L. Why biologics and biosimilars remain so expensive: despite two wins for biosimilars, the supreme court’s recent rulings do not solve fundamental barriers to competition. Drugs, 78, 1777–1781 (2018).

33. Hempel, G. et al. Cytotoxicity of dimethylacetamide and pharmacokinetics in children receiving intravenous busulfan. J Clin Oncol, 25, 1772–1778 (2007).

34. Wéra, O., Lancellotti, P. & Oury, C. The dual role of neutrophils in inflammatory bowel diseases. J Clin Med, 5, 118 (2016).

35. Rugtveit, J., Brandtzaeg, P., Halstensen, T. S., Fausa, O. & Scott, H. (1994) Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut. 1994;35:669-74.

36. Matricon, J., Barnich, N. & Ardid, D. Immunopathogenesis of inflammatory bowel disease. Self Nonself, 1, 299–309 (2010).

37. Reinisch, W. et al. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol, 94, 2156–2164 (1999).

38. Ligumsky, M., Simon, P. L., Karmeli, F. & Rachmilewitz, D. Role of interleukin 1 in inflammatory bowel disease—enhanced production during active disease., 31, 686–689 (1990).

39. Li, M. C. & He, S. H. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol, 10, 620–625 (2004).

40. Keubler, L. M., Buettner, M., Häger, C. & Bleich, A. A multi-hit model: colitis lessons from the interleukin-10-deficient mouse. Inflamm Bowel Dis, 21, 1967–1975 (2015).

41. Laroui, H. et al. Dextran sodium sulfate (DSS) induces colitis in mice by forming nano-lipocomplexes with medium-chain-length fatty acids. PLoS ONE, 7 (3), e32084 (2012).

42. Lee, J., Rhee, M. H., Kim, E. & Cho, J. Y. BAY 11-7082 is a broad spectrum inhibitor with anti-inflammatory activity against multiple targets. Mediators Inflamm, https://doi.org/10.1155/2012/416 (2012).

Figures
Figure 1

DMA attenuates IL-8 secretion from LPS-stimulated colonic epithelial cells. Levels of IL-8 in cell supernatants after stimulation with 1 g ml−1 LPS in the absence or presence of increasing concentrations of DMA as shown. A, HT-29 cells; B, HCT-116 cells; C, SW620 cells. **P<.01; ***P<.001; ****P<.0001.
Figure 2

DMA attenuates IL-8 secretion from TNF-stimulated colonic epithelial cells. Levels of IL-8 in cell supernatants after stimulation with 40 ng mL-1 TNF in the absence or presence of increasing concentrations of DMA as shown. A, HT-29 cells; B, SW620 cells. **P<.01; ***P<.001.

Figure 3

DMA attenuates pro-inflammatory cytokine secretion from LPS-stimulated THP-1 cells. Levels of various cytokines in cell supernatants after stimulation with 1 g ml-1 LPS in the absence or presence of increasing concentrations of DMA. BAY 11-7082 (5 M), an NF-kB inhibitor [42] is included as a positive control. A, IL-1; B, IL-6; C, IL-8; D, MCP-1; E, IL-10. **P<.01; *** P<.001; ****P<.0001.
Figure 4

DMA prevents IkBa degradation in THP-1 cells. Levels of IkBa in THP-1 cell lysates after stimulation with LPS in the absence or presence of increasing concentrations of DMA. BAY 11-7082 (5 mM), an NF-kB inhibitor, is included as a positive control.
Figure 5

DMA decreases HMGB1 secretion from LPS-stimulated RAW 264.7 cells. Levels of HMGB1 in cell supernatants after stimulation with 1 mg ml-1 LPS in the absence or presence of increasing concentrations of DMA. ****P<.0001.
Figure 6

DMA prevents DSS-induced colitis. Hematoxylin and eosin stained tissue sections of colon from C57Bl/6 mice treated with 2.5% DSS in the absence or presence of rescue by daily treatments of 2.1 g/kg DMA administered ip. A, sham; B, DSS with no DMA treatment; C, DSS plus DMA rescue. Arrow indicates crypt abscess. Original magnification 200X.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- FigS1.docx
- FigS2.docx
- FigS3.docx
- FigS4.docx
- SuppTable1.docx